logo
What Is the Medicare Beneficiary Ombudsman?

What Is the Medicare Beneficiary Ombudsman?

Health Line02-06-2025
The Medicare beneficiary ombudsman (MBO) is a representative who works on behalf of Medicare enrollees to resolve Medicare-related complaints, ensure access to information, and improve the program.
An ombudsman is a person who reviews how an organization operates, investigates complaints, and helps resolve those complaints. They typically work as a client advocate within an organization or business. The MBO serves this function within the Medicare program.
Learn more about the services the MBO provides and how to connect.
What is the role of a Medicare beneficiary ombudsman?
Congress formed the MBO role in 2003. The person in this role assists Medicare enrollees in various areas, including handling complaints, appeals, and requests for information.
The general duties of the MBO, as outlined in section 1808 of the Social Security Act, are to:
receive and help resolve complaints and inquiries that Medicare beneficiaries and other stakeholders make
work with representatives of health insurance counseling programs to provide information and resources to beneficiaries
report to Congress on ways to improve the administration of Medicare
In addition to addressing complaints, some of the specific issues enrollees may have to address with an MBO include:
Appeals: If you disagree with a Medicare payment or coverage determination, you can file an appeal. The MBO can assist you with this process.
Enrollment concerns: If you have issues when leaving a Medicare Advantage (Part C) plan or joining a new plan, the MBO can assist you.
Claims: If you need to file a Medicare claim, the MBO can help you through the process or troubleshoot issues that arise.
What are a beneficiary's rights under Medicare?
As a Medicare beneficiary, you have various clearly outlined rights and protections. The MBO exists to help preserve those rights and ensure fair treatment of all Medicare beneficiaries.
It can be helpful for Medicare enrollees to periodically review their rights to understand what types of treatment and services they can expect.
A Medicare beneficiary's rights include:
fair and courteous treatment
privacy of personal and health information
access to appropriate healthcare professionals for medically necessary services
clear, understandable information access regarding coverage, plan options, costs, and more
Medicare designs its protections to keep beneficiaries up to date on coverage status and prevent unexpected costs. They come into play when Medicare may not cover a service, or you reach the end of Medicare coverage.
A beneficiary's protections include:
receiving an Advance Beneficiary Notice (ABN) of Noncoverage for any services that Medicare doesn't cover
getting a Notice of Medicare Noncoverage at least 2 days before covered home health services end
acquiring a Hospital-Issued Notice of Noncoverage (HINN) for inpatient services that Medicare Part A doesn't cover
If you've experienced violations of your rights or protections or have an issue with Medicare noncoverage, you can contact the MBO for assistance.
How to contact a Medicare beneficiary ombudsman
Not all Medicare-related questions should go directly to the MBO. Other contact points may be more suitable based on your coverage and the nature of your question or concern.
If you're a Medicare Advantage or Part D enrollee, contact your insurance carrier with any questions or complaints about your plan. You can generally find contact information for the plan on the back of your insurance card.
If you have questions about Original Medicare or need help with issues that a private insurance carrier can't address, you can contact Medicare by phone at 800-633-4227.
If you have general questions or would like free, unbiased Medicare counseling, you can contact your local State Health Insurance Assistance Program (SHIP).
Finally, if you have questions that the channels above can't resolve, you can direct your query to the MBO. You can do so by contacting Medicare by phone at 800-633-4227 and requesting your case's submission to the MBO.
Summary
The MBO has a role within the Medicare program to provide customer service and advocacy.
The MBO can assist Medicare beneficiaries with resolving complaints and accessing important information. They also work to improve Medicare's administration by submitting an annual report to Congress on its operation.
If you have a concern requiring the MBO's attention, you can contact Medicare by phone and explain the situation.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ghislaine Maxwell's immunity request denied by House Oversight Committee
Ghislaine Maxwell's immunity request denied by House Oversight Committee

Fox News

time13 minutes ago

  • Fox News

Ghislaine Maxwell's immunity request denied by House Oversight Committee

The House Oversight Committee, led by GOP Chairman James Comer, said it "will not consider" a request from Ghislaine Maxwell's attorneys asking for immunity in exchange for her testimony to Congress. The former accomplice and girlfriend of Jeffrey Epstein was hit with a subpoena last week to testify before Congress – from prison – amid a probe from lawmakers seeking to uncover more information about the disgraced financier's sex crimes. The subpoenaed deposition was scheduled for August 11. On Tuesday, Maxwell's attorneys sent a letter to Chairman Comer indicating she would invoke her Fifth Amendment rights and stay silent in front of Congress, unless the immunity request was agreed upon. In Maxwell's immunity request, her attorney's offer clemency as a possible solution as well, indicating Maxwell "would be willing—and eager—to testify openly and honestly, in public, before Congress" if it were granted to her. "The Oversight Committee will respond to Ms. Maxwell's attorney soon, but it will not consider granting congressional immunity for her testimony," a spokesperson told Fox News Digital after receiving the letter. In their letter to Comer, Maxwell's attorneys said their client's testimony could pose both legal and security risks for their client. Maxwell's legal team also requested questions their client would be asked in advance of her testimony in front of Congress, but the Oversight spokesperson did not directly speak to that request. Another request from Maxwell's attorneys was that the deposition date be delayed until after the Supreme Court rules on Maxwell's latest bid for an appeal. On Monday, Maxwell's attorneys asked the High Court to hear their client's appeal in her 2021 sex trafficking conviction, arguing the federal government "has an obligation to honor" a 2007 non-prosecution agreement that they believe should shield her from criminal charges. "Ms. Maxwell should never have been charged in the first place. In 2008, the United States government promised, in writing, that she would not be prosecuted," Maxwell's attorneys wrote in their correspondence to Comer, adding she did not receive a fair trial when convicted in the Southern District of New York for sex trafficking in 2021. "[The government] broke that promise only after Mr. Epstein died in 2019—at which point Ms. Maxwell became a convenient scapegoat." According to the attorneys, during Maxwell's case in the Southern District of New York prosecutors "wrongfully convinced the trial judge to unfairly limit Ms. Maxwell from presenting her defense, and at least one juror lied about a material fact during voir dire in order to serve on the jury." Fox News Digital reached out to Maxwell's attorney, David Oscar Markus, for comment, but did not immediately receive a response.

This is what judicial overreach looks like
This is what judicial overreach looks like

Washington Post

time13 minutes ago

  • Washington Post

This is what judicial overreach looks like

This White House has aggressively tried to withhold federal money from programs it dislikes. Those efforts have rightly faced scrutiny in the courts because the Constitution gives Congress the power of the purse. A case out of Massachusetts is different. There, a federal judge has blocked an act of Congress — not an executive order, but legislation — steering Medicaid funds away from abortion providers. Allocating public money is Congress's core competency. Yet District Judge Indira Talwani not only countermanded Congress's spending choice in a preliminary injunction, she refused to stay her ruling pending appeal. This is the kind of lower-court activism that gives the Trump administration fodder for its attacks on judges.

Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?

Yahoo

time18 minutes ago

  • Yahoo

Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, that have led investors to bet against the company. The company reported disappointing data from two late-stage studies for its next-generation subcutaneous obesity candidate, CagriSema, a follow-up drug to Wegovy. In these studies, CagriSema demonstrated a lower-than-expected reduction in body weight, despite meeting the primary endpoints. Earlier, Medicare announced that it will not cover costly weight-loss drugs, including NVO's Wegovy (semaglutide), as obesity remains unclassified as a disease. Consequently, these medications, often viewed as cosmetic, may become less accessible to patients. Novo Nordisk is also currently facing a major transition in its executive management as CEO Lars Fruergaard Jørgensen will step down due to market headwinds and a decline in the company's stock since mid-2024. The search for his successor is currently underway. Moreover, Novo Nordisk faces intense competition from its arch-rival Eli Lilly LLY in the diabetes and obesity care market. LLY markets its tirzepatide injections as Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Zepbound had earlier outperformed Novo Nordisk's Wegovy (20.2% compared with 13.7%, respectively) in a weight-loss head-to-head study. This could lead to a shift in patient preference from Wegovy to Zepbound, potentially resulting in a loss of market share. Lilly has also been taking significant strides in the development of oral therapies for obesity, effectively putting pressure on Novo Nordisk. In April 2025, LLY reported first phase III success for its oral GLP-1 candidate, orforglipron, in lowering blood glucose and promoting weight loss in T2D patients. Oral pills could boost adherence over injections. Additionally, NVO recently ended its collaboration agreement with Hims & Hers Health, which will temporarily hurt its objective of increasing Wegovy's patient access, resulting in a slowdown in obesity market share gain. However, not all is wrong at NVO. Novo Nordisk is making good progress with its pipeline, which includes several other new candidates for T2D and obesity. The company also has strong fundamentals, and the untapped nature of the obesity market makes us believe that the setback is temporary. Let's dig deeper and understand the company's strengths and weaknesses to understand how to play the stock after the recent price drop. Semaglutide - NVO's Growth Engine Novo Nordisk's success in recent years has been driven by its popular semaglutide-based GLP-1 products — Ozempic (injection) and Rybelsus (oral) for T2D, and Wegovy for obesity. The company holds a strong position in diabetes care, with one of the industry's broadest portfolios and a global diabetes market share of 33.3% as of March 2025, led by Rybelsus, Ozempic, and Victoza. It also dominates the GLP-1 segment with a 54% global market share. Wegovy is a major revenue driver, with first-quarter 2025 sales up 83% to DKK 17.4 billion on strong prescription growth. Ozempic also continues to boost overall revenues. To protect its lead amid competition from Lilly, Novo Nordisk is heavily investing in its GLP-1 manufacturing capacity. As of July 1, CVS Caremark, a major pharmacy benefit manager, has designated Wegovy as its preferred GLP-1 therapy for weight loss. Novo Nordisk is expanding semaglutide's reach through new indications. Wegovy is now approved for reducing major cardiovascular events, easing HFpEF symptoms, and relieving osteoarthritis-related knee pain in obesity. Ozempic's label includes use in T2D patients with cardiovascular and kidney disease. The FDA is reviewing Novo Nordisk's application for a 25 mg oral semaglutide for obesity, with a decision expected by year-end. NVO has also filed Rybelsus for cardiac event prevention in T2D and is studying semaglutide for liver disease. A 7.2 mg Wegovy dose, showing up to 25% weight loss in the STEP UP study, is under EU review. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the EU. Beyond GLP-1s, Novo Nordisk is expanding into rare diseases, with regulatory plans for Mim8 (hemophilia A) and EU approval of Alhemo (hemophilia A/B with inhibitors). It also expects to file for semaglutide in metabolic dysfunction–associated steatohepatitis in both the United States and the EU in 2025. NVO Focuses on Next-Generation Drugs for Obesity Novo Nordisk is also developing several next-generation obesity candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced weight loss candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. The company is already planning its regulatory submission in 2026. Novo Nordisk is also developing a small-molecule oral CB1 inverse agonist, monlunabant, in a mid-stage study. The company is currently gearing up to advance Amycretin, an investigational unimolecular GLP-1 and amylin receptor agonist, for weight management into late-stage development. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases. Competition Heating Up in the Obesity Space Competition in the obesity market is heating up as the obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Several other companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and T2D, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics recently launched the late-stage VANQUISH program for subcutaneous VK2735 in obesity and T2D, following the initiation of the mid-stage VENTURE study on the oral version earlier this year. NVO's Stock Price, Valuation, Estimates In the past year, Novo Nordisk shares have lost 51.1% compared with the industry's 17% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 16 forward earnings, which is higher than 15.12 for the industry. However, the stock is trading much below its five-year mean of 29.25. NVO Stock Valuation Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.85 to $3.98 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have declined from $4.65 to $4.59. NVO Estimate Movement Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.55% for the large drugmaker industry, as seen in the chart below. NVO Return on Equity Image Source: Zacks Investment Research Here's How to Play NVO Stock Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), has the potential to boost shareholders' wealth in the future. Despite past pipeline and regulatory setbacks, along with the ongoing transition in leadership, we remain confident that NVO is a good stock to retain. The company operates in a lucrative market that is rapidly expanding. Its strong year-over-year revenues and profits, fueled by rising demand for Wegovy and Ozempic, suggest long-term potential. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The company is actively working to expand the approved uses of its key semaglutide products, Wegovy, Ozempic, and Rybelsus, which could significantly increase the eligible patient pool and drive future revenues. However, Eli Lilly remains a formidable adversary in the obesity market space, which threatens NVO's market share. Hence, we can conclude that investors currently holding the NVO stock should not get spooked by the recent downtrend in the stock price. In fact, new Investors can use the current dip in the price to acquire the stock to enjoy significant value creation in the long run. Short-term investors are, however, advised to steer clear of the stock to avoid near-term volatility. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store